Truist Securities Reiterates Buy on Encompass Health, Raises Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Encompass Health and increased the price target from $108 to $116.
October 30, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on Encompass Health and increased the price target from $108 to $116.
The reiteration of a Buy rating and an increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100